Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) Meeting Abstract
| Authors: | Wong, W.; Adkins, D. R.; Misleh, J. G.; Lorch, J.; Grewal, J. S.; Russell, J.; Cetnar, J.; Ho, A. L.; Chen, K.; Aysola, K.; Thomas, J. |
| Abstract Title: | Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S622 |
| End Page: | S623 |
| Language: | English |
| ACCESSION: | WOS:001326612901173 |
| DOI: | 10.1016/j.annonc.2024.08.929 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 868P -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
